Eargo, Inc. Announces Upsized Pricing of Initial Public Offering
Eargo has announced the pricing of its initial public offering (IPO) of 7,851,852 shares of common stock at $18.00 per share, aiming to raise approximately $141.3 million. The company has granted underwriters a 30-day option to purchase an additional 1,177,777 shares. Eargo's shares will begin trading on the Nasdaq under the ticker symbol EAR on October 16, 2020. The IPO's closing is expected on October 20, 2020, subject to standard closing conditions.
- Initial public offering priced at $18.00 per share, raising $141.3 million.
- Underwriters granted a 30-day option for additional shares, indicating demand.
- Potential dilution of existing shares if underwriters exercise their option for additional shares.
SAN JOSE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of
J.P. Morgan and BofA Securities acted as lead book-running managers and as representatives of the underwriters for the offering. Wells Fargo Securities and William Blair acted as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus‐eq_fi@jpmorgan.com or by telephone at (866) 803‐9204, or from BofA Securities, NC1‐004‐03‐43, 200 North College Street, 3rd Floor, Charlotte, NC 28255‐0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com.
A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Eargo
Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Eargo developed the Eargo solution to create a hearing aid that consumers actually want to use. Eargo’s innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost.
Investor Contact
Nick Laudico
Vice President of Investor Relations
ir@eargo.com
Media Contact
Aaron Murphy
eargo@edelman.com
FAQ
What is the share price for Eargo's IPO?
When will Eargo's stock start trading?
What is the ticker symbol for Eargo?
How much capital is Eargo looking to raise in the IPO?